Idorsia Pharmaceutical. has filed a patent for compounds of Formula (I) that can be used as medicaments, particularly as Kv7 openers. The patent also covers the preparation of these compounds, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The compounds have various substituents and can be used for therapeutic purposes. GlobalData’s report on Idorsia Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Idorsia Pharmaceutical Ltd - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Idorsia Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Idorsia Pharmaceutical's grant share as of September 2023 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230303486A1) describes a compound of Formula (I) and its various derivatives. The compound has potential applications in the prevention and treatment of diseases such as epilepsy, myokymia, tinnitus, hearing disorders, neuropathic and inflammatory pain, psychiatric disorders, substance use disorders, neurological disorders, and diseases affecting smooth muscles. The compound can exist in different forms, with variations in the substituents attached to the different parts of the molecule.

The compound of Formula (I) consists of various components represented by X1, X2, X3, R1, RX4, R2A, R2B, L, R3, R4, R5, and R6. These components can be hydrogen, halogen, alkyl, alkoxy, hydroxy, cycloalkyl, fluoroalkyl, cyano, cyanoalkyl, or heteroaryl groups. The compound can also form rings of 3-6 members, containing carbon and oxygen atoms. The compound can be in the form of a salt as well.

The patent also describes specific compounds falling under the scope of Formula (I), such as 1-(3-difluoromethyl-bicyclo[1.1.1]pent-1-yl)-3-(3-trifluoromethyl-benzyl)-urea and 1-(3-(difluoromethyl)cyclobutyl)-3-(3-(trifluoromethyl)benzyl)urea. These compounds can be used as active principles in pharmaceutical compositions, along with therapeutically inert excipients, for the prevention and treatment of the mentioned diseases.

In summary, the patent presents a compound of Formula (I) and its derivatives, which have potential applications in the prevention and treatment of various diseases. The compound can exist in different forms, with variations in the substituents attached to its different parts. Specific compounds falling under this scope are also disclosed, along with their potential use in pharmaceutical compositions.

To know more about GlobalData’s detailed insights on Idorsia Pharmaceutical, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies